(Q37880347)

24 August 2017

0 references

1 reference

title

A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). (English)

1 reference

enterotoxigenic Escherichia coli

24 August 2017

0 references

experimental infection

1 reference

1 reference

1 reference

Chad K Porter

1

1 reference

24 August 2017

Mark S Riddle

2

1 reference

24 August 2017

David R Tribble

3

1 reference

24 August 2017

A Louis Bougeois

4

1 reference

24 August 2017

Robin McKenzie

5

1 reference

24 August 2017

Sandra D Isidean

6

1 reference

24 August 2017

Peter Sebeny

7

1 reference

24 August 2017

Stephen J Savarino

8

1 reference

24 August 2017

language of work or name

English

0 references

publication date

25 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

35

1 reference

24 August 2017

page(s)

5869-5885

1 reference

Pathogenesis of Escherichia coli diarrhea

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Vaccines against enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Meta-analysis of continuous outcome data from individual patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

A multilevel model framework for meta-analysis of clinical trials with binary outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Role of Escherichia coli colonisation factor antigen in acute diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Sensitivity and specificity of DNA probes with the stool blot technique for detection of Escherichia coli enterotoxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Clinical features and duration of traveler's diarrhea in relation to its etiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Bismuth revisited: an effective way to prevent travelers' diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Use of bismuth subsalicylate for the prevention of travelers' diarrhea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Clinical features, antimicrobial susceptibility and toxin production in Vibrio cholerae O139 infection: comparison with V. cholerae O1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Enterotoxigenic Escherichia coli TibA glycoprotein adheres to human intestine epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Identification of a gene within a pathogenicity island of enterotoxigenic Escherichia coli H10407 required for maximal secretion of the heat-labile enterotoxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Identification and molecular characterization of EatA, an autotransporter protein of enterotoxigenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

The EtpA exoprotein of enterotoxigenic Escherichia coli promotes intestinal colonization and is a protective antigen in an experimental model of murine infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

The ethical challenge of infection-inducing challenge experiments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Postinfectious irritable bowel syndrome--a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Infectious gastroenteritis and risk of developing inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Short- and long-term effects of bacterial gastrointestinal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Lack of prophylactic efficacy of an enteric-coated bovine hyperimmune milk product against enterotoxigenic Escherichia coli challenge administered during a standard meal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Diarrhoea associated with heat-stable enterotoxin-producing strains of Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

Molecular characterization of the tia invasion locus from enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

7 January 2021

Detection of the enteroaggregative Escherichia coli heat-stable enterotoxin 1 gene sequences in enterotoxigenic E. coli strains pathogenic for humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

7 January 2021

Immunity to Enterotoxigenic Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

7 January 2021

Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

7 January 2021

Characterization of an enterotoxigenic Escherichia coli strain from Africa expressing a putative colonization factor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.021

7 January 2021

10.1016/J.VACCINE.2011.05.021

Identifiers

DOI

1 reference

24 August 2017

1 reference